Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure BioSciences' latest Barocycler machine's credentials featured at scientific meetings

The machine can process and analyse under pressure up to 16 samples simultaneously, potentially leading to the discovery of new drugs and treatments.
Pressure BioSciences' latest Barocycler machine's credentials featured at scientific meetings
The group develops and sells proprietary lab instruments to the life sciences sample preparation market

Pressure cycling technology (PCT) specialist Pressure BioSciences Inc (OTCMKTS:PBIO) says its recently released Barocycler 2320EXTREME instrument has received plaudits at several European scientific meetings - boosting its potential in the European biopharma markets.

The machine can process and analyse under pressure up to 16 samples simultaneously, potentially leading to the discovery of new drugs and treatments.

It is estimated that there are over 1bn FFPE (formalin-fixed, paraffin-embedded) tissue samples in the world, collected over a span of many decades," says Dr Nathan Lawrence, the vice president of marketing and sales at Pressure BioSciences.

"Complete clinical histories for such samples are often available, including such important data as disease progression and outcome, medications taken, and symptoms.

"More effective analyses of such samples, enabled by methods such as PCT, is expected to result in a bonanza of new and important biomarker discoveries. These discoveries open pivotal opportunities for development of new drugs, therapies, and disease-prevention strategies."

SCIEX, the co-marketing partner of PBI, organized an all-day seminar focused on the latest applications of mass spectrometry in digital biobanking in Munich, which discussed the Barocycler 2320EXT.

The 55th European High Pressure Research Group  took place in Poznan, Poland and looked at high pressure research.

The 16th Human Proteome Organization (HUPO) World Congress took place in Dublin, Ireland.

The OTCQB-listed firm develops and sells proprietary laboratory instrumentation and associated consumables to the US$6bn life sciences sample preparation market.

Shares added 3.24% to US$4.14 in New York.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
1511808112_surgeon.jpg
November 27 2017
In a letter to stakeholders, George Adams, the president and chief executive, highlighted that the device would "reduce the cost of its equipment significantly"
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use